Every material Form 8-K OS Therapies Inc has filed with the SEC since September 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OS Therapies said on October 15, 2026 that seven holders exercised or pre-funded 5,517,253 existing warrants at a reduced price of $1.30 per share, bringing in about $7.2 million in gross proceeds before fees. In exchange, the company issued new five-year warrants for the same number of shares at $1.40, and the company says the offer could bring about $12.3 million in total if all existing warrants are exercised. Because the new warrants add potential share issuance, the deal provides near-term capital but also raises potential dilution for existing shareholders.
Initial closing on October 15, 2026: seven holders exercised or pre-funded warrants for 5,517,253 shares at $1.30 per share, for about $7.2 million gross.
New warrants issued for 5,517,253 shares at $1.40 per share, expiring five years from issuance; if all existing warrants are exercised, up to 9,448,060 new warrant shares could be issued.
Company agreed to pay a solicitation agent a 7.0% cash fee on gross proceeds plus a $25,000 expense allowance; the offer expires at 11:59 p.m. Eastern on October 30, 2026.
Company plans to file a resale registration statement by November 30, 2026, and says proceeds will fund Herlystic clinical, regulatory and commercial preparation work.
OS Therapies appointed Frank Knuettel II as chief financial officer and Kerry Clem as chief commercial officer, both effective September 29, 2026. Christopher P. Acevedo ceased serving as CFO and will continue to provide services in a consulting capacity. The company's accompanying October 1, 2026 press release also said most outstanding accounts payable were delayed to the second quarter of 2027, which it said gives time to align cash flow needs with anticipated cash inflows.
Knuettel, 60, becomes CFO with a base salary of $300,000 per year, rising to $360,000 after a material transaction, and an initial grant of options on 750,000 shares and 250,000 RSUs.
Clem, 57, becomes CCO with a base salary of $300,000 per year and options on 700,000 shares plus 200,000 RSUs, subject to board approval.
Acevedo ceased serving as CFO in connection with Knuettel's appointment and will continue as a consultant.
The press release said the company received over $3 million in VAT refunds to date and that most outstanding accounts payable were delayed to the second quarter of 2027.
OS Therapies filed a prospectus supplement covering the resale of up to 5,874,094 common shares by selling stockholders under its effective Form S-3 registration statement. This 8-K provides the legal opinion from its counsel on the legality of those shares.
Prospectus supplement filed September 10, 2026 under Form S-3 (File No. 333-289443), filed August 8, 2025 and declared effective August 25, 2025
Covers resale of up to 5,874,094 common shares by selling stockholders
Legal opinion from Olshan Frome Wolosky LLP attached as Exhibit 5.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OS Therapies Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →